Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 56

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

The Status of p53 Oligomeric and Aggregation States in Cancer

de Oliveira, Guilherme A. P., Petronilho, Elaine C., Pedrote, Murilo M., Marques, Mayra A., Vieira, Tuane C. R. G., Cino, Elio A., Silva, Jerson L.·2020·Biomolecules
DOI 10.3390/biom10040548
Open this paper in CoChat — free account

Abstract

Despite being referred to as the guardian of the genome, when impacted by mutations, p53 can lose its protective functions and become a renegade. The malignant transformation of p53 occurs on multiple levels, such as altered DNA binding properties, acquisition of novel cellular partners, or associating into different oligomeric states. The consequences of these transformations can be catastrophic. Ongoing studies have implicated different oligomeric p53 species as having a central role in cancer biology; however, the correlation between p53 oligomerization status and oncogenic activities in cancer progression remains an open conundrum. In this review, we summarize the roles of different p53 oligomeric states in cancer and discuss potential research directions for overcoming aberrant p53 function associated with them. We address how misfolding and prion-like amyloid aggregation of p53 seem to play a crucial role in cancer development. The misfolded and aggregated states of mutant p53 are prospective targets for the development of novel therapeutic strategies against tumoral diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biom10040548

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 76

  1. Lane, 1979, T antigen is bound to a host protein in SV40-transformed cells, Nature, 278, 261, 10.1038/278261a0 · DOI · Paper page
  2. Linzer, 1979, Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells, Cell, 17, 43, 10.1016/0092-8674(79)90293-9 · DOI · Paper page
  3. Rangel, 2015, Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer, Front. Oncol., 5, 97
  4. Muller, 2013, p53 mutations in cancer, Nat. Cell Biol., 15, 2, 10.1038/ncb2641 · DOI · Paper page
  5. Costa, 2016, Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?, Cold Spring Harb. Perspect. Biol., 8, a023614, 10.1101/cshperspect.a023614 · DOI
  6. Kastan, 1992, A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia, Cell, 71, 587, 10.1016/0092-8674(92)90593-2 · DOI · Paper page
  7. Lowe, 1993, p53 is required for radiation-induced apoptosis in mouse thymocytes, Nature, 362, 847, 10.1038/362847a0 · DOI · Paper page
  8. Halazonetis, 1993, Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants, EMBO J., 12, 5057, 10.1002/j.1460-2075.1993.tb06199.x · DOI · Paper page
  9. Joerger, 2016, The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches, Annu. Rev. Biochem., 85, 375, 10.1146/annurev-biochem-060815-014710 · DOI · Paper page
  10. Saito, 2003, Phosphorylation site interdependence of human p53 post-translational modifications in response to stress, J. Biol. Chem., 278, 37536, 10.1074/jbc.M305135200 · DOI · Paper page
  11. Appella, 2001, Post-translational modifications and activation of p53 by genotoxic stresses, Eur. J. Biochem., 268, 2764, 10.1046/j.1432-1327.2001.02225.x · DOI · Paper page
  12. Ferreon, 2009, Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2, Proc. Natl. Acad. Sci. USA, 106, 6591, 10.1073/pnas.0811023106 · DOI · Paper page
  13. Sakamuro, 1997, The polyproline region of p53 is required to activate apoptosis but not growth arrest, Oncogene, 15, 887, 10.1038/sj.onc.1201263 · DOI · Paper page
  14. Gu, 1997, Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain, Cell, 90, 595, 10.1016/S0092-8674(00)80521-8 · DOI · Paper page
  15. Espinosa, 2001, Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment, Mol. Cell, 8, 57, 10.1016/S1097-2765(01)00283-0 · DOI · Paper page
  16. Leroy, 2014, TP53 mutations in human cancer: Database reassessment and prospects for the next decade, Hum. Mutat., 35, 672, 10.1002/humu.22552 · DOI · Paper page
  17. Taylor, 1996, p53 mutations in bladder tumors from arylamine-exposed workers, Cancer Res., 56, 294
  18. Sun, 1996, A novel p53 germline alteration identified in a late onset breast cancer kindred, Oncogene, 13, 407
  19. Bullock, 2000, Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: Definition of mutant states for rescue in cancer therapy, Oncogene, 19, 1245, 10.1038/sj.onc.1203434 · DOI · Paper page
  20. Silva, 2018, Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer, Acc. Chem. Res., 51, 181, 10.1021/acs.accounts.7b00473 · DOI
  21. Milner, 1991, Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation, Cell, 65, 765, 10.1016/0092-8674(91)90384-B · DOI · Paper page
  22. Vaughan, 2012, p53 mutants induce transcription of NF-kappaB2 in H1299 cells through CBP and STAT binding on the NF-kappaB2 promoter and gain of function activity, Arch. Biochem. Biophys., 518, 79, 10.1016/j.abb.2011.12.006 · DOI
  23. Zhu, 2015, Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth, Nature, 525, 206, 10.1038/nature15251 · DOI · Paper page
  24. Will, 1998, Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing, Proc. Natl. Acad. Sci. USA, 95, 13681, 10.1073/pnas.95.23.13681 · DOI
  25. Fontemaggi, 2011, ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters, OMICS, 15, 305, 10.1089/omi.2010.0084 · DOI
  26. Liu, 2011, TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73, Mol. Cell Biol., 31, 4464, 10.1128/MCB.05574-11 · DOI
  27. Girardini, 2011, A Pin1/mutant p53 axis promotes aggressiveness in breast cancer, Cancer Cell, 20, 79, 10.1016/j.ccr.2011.06.004 · DOI · Paper page
  28. Martynova, 2012, Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63, Oncotarget, 3, 132, 10.18632/oncotarget.447 · DOI
  29. Song, 2007, p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM, Nat. Cell Biol., 9, 573, 10.1038/ncb1571 · DOI · Paper page
  30. Restle, 2008, Dissecting the role of p53 phosphorylation in homologous recombination provides new clues for gain-of-function mutants, Nucleic Acids Res., 36, 5362, 10.1093/nar/gkn503 · DOI · Paper page
  31. Rajagopalan, 2011, Single-Molecule characterization of oligomerization kinetics and equilibria of the tumor suppressor p53, Nucleic Acids Res., 39, 2294, 10.1093/nar/gkq800 · DOI · Paper page
  32. Jeffrey, 1995, Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms, Science, 267, 1498, 10.1126/science.7878469 · DOI · Paper page
  33. Stenger, 1992, Formation of stable p53 homotetramers and multiples of tetramers, Mol. Carcinog., 5, 102, 10.1002/mc.2940050204 · DOI
  34. Wang, 1995, Interaction of p53 with its consensus DNA-binding site, Mol. Cell Biol., 15, 2157, 10.1128/MCB.15.4.2157 · DOI
  35. Stenger, 1994, p53 oligomerization and DNA looping are linked with transcriptional activation, EMBO J., 13, 6011, 10.1002/j.1460-2075.1994.tb06947.x · DOI · Paper page
  36. Okorokov, 2006, The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity, EMBO J., 25, 5191, 10.1038/sj.emboj.7601382 · DOI · Paper page
  37. Kearns, 2016, Two p53 tetramers bind one consensus DNA response element, Nucleic Acids Res., 44, 6185, 10.1093/nar/gkw215 · DOI
  38. Vyas, 2017, Diverse p53/DNA binding modes expand the repertoire of p53 response elements, Proc. Natl. Acad. Sci. USA, 114, 10624, 10.1073/pnas.1618005114 · DOI
  39. Pedrote, 2020, Oncogenic Gain of Function in Glioblastoma Is Linked to Mutant p53 Amyloid Oligomers, iScience, 23, 100820, 10.1016/j.isci.2020.100820 · DOI
  40. Gaglia, 2013, Activation and control of p53 tetramerization in individual living cells, Proc. Natl. Acad. Sci. USA, 110, 15497, 10.1073/pnas.1311126110 · DOI
  41. Xu, 2011, Gain of function of mutant p53 by coaggregation with multiple tumor suppressors, Nat. Chem. Biol., 7, 285, 10.1038/nchembio.546 · DOI · Paper page
  42. Stommel, 1999, A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking, EMBO J., 18, 1660, 10.1093/emboj/18.6.1660 · DOI · Paper page
  43. Katz, 2018, Wild-type and cancer-related p53 proteins are preferentially degraded by MDM2 as dimers rather than tetramers, Genes Dev., 32, 430, 10.1101/gad.304071.117 · DOI
  44. Rangel, 2012, Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: Implications for cancer, J. Biol. Chem., 287, 28152, 10.1074/jbc.M112.340638 · DOI · Paper page
  45. Ghosh, 2017, p53 amyloid formation leading to its loss of function: Implications in cancer pathogenesis, Cell Death Differ., 24, 1784, 10.1038/cdd.2017.105 · DOI
  46. Clos, 2013, Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity, Biochem. Biophys. Res. Commun., 430, 963, 10.1016/j.bbrc.2012.11.130 · DOI
  47. Soteras, 2015, p53 protein aggregation promotes platinum resistance in ovarian cancer, Oncogene, 34, 3605, 10.1038/onc.2014.296 · DOI
  48. Pedrote, 2019, Loss of the p53 transactivation domain results in high amyloid aggregation of the Delta40p53 isoform in endometrial carcinoma cells, J. Biol. Chem., 294, 9430, 10.1074/jbc.RA119.007566 · DOI
  49. Ishimaru, 2003, Fibrillar aggregates of the tumor suppressor p53 core domain, Biochemistry, 42, 9022, 10.1021/bi034218k · DOI · Paper page
  50. Ishimaru, 2003, Conversion of Wild-type p53 Core Domain into a Conformation that Mimics a Hot-spot Mutant, J. Mol. Biol., 333, 443, 10.1016/j.jmb.2003.08.026 · DOI
  51. Levy, 2011, Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors, Int. J. Biochem. Cell Biol., 43, 60, 10.1016/j.biocel.2010.10.017 · DOI · Paper page
  52. Wang, 2013, Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase, Neurol. Sci., 34, 1421, 10.1007/s10072-012-1257-9 · DOI
  53. Klibanov, 2001, Accumulation of soluble and nucleolar-associated p53 proteins following cellular stress, J. Cell Sci., 114, 1867, 10.1242/jcs.114.10.1867 · DOI
  54. Latonen, 2019, Phase-to-Phase with Nucleoli—Stress Responses, Protein Aggregation and Novel Roles of RNA, Front. Cell Neurosci., 13, 151, 10.3389/fncel.2019.00151 · DOI
  55. Audas, 2016, Adaptation to Stressors by Systemic Protein Amyloidogenesis, Dev. Cell, 39, 155, 10.1016/j.devcel.2016.09.002 · DOI · Paper page
  56. Silva, 2016, The “Jekyll and Hyde” Actions of Nucleic Acids on the Prion-like Aggregation of Proteins, J. Biol. Chem., 291, 15482, 10.1074/jbc.R116.733428 · DOI
  57. Kamagata, 2020, Liquid-like droplet formation by tumor suppressor p53 induced by multivalent electrostatic interactions between two disordered domains, Sci. Rep., 10, 580, 10.1038/s41598-020-57521-w · DOI
  58. Cordeiro, 2019, Modulation of p53 and prion protein aggregation by RNA, Biochim. Biophys. Acta Proteins Proteom., 1867, 933, 10.1016/j.bbapap.2019.02.006 · DOI
  59. Yang, D.S.S.A., Davtyan, A., Fathi, M., Safari, M.S., Klindziuk, A., Barton, M.C., Varadarajan, N., Kolomeisky, A.B., and Vekilov, P.G. (2020). Mesoscopic Liquid Clusters Represent a Distinct Condensate of Mutant p53. bioRxiv. · DOI
  60. Yoshida, 2004, Binding of RNA to p53 regulates its oligomerization and DNA-binding activity, Oncogene, 23, 4371, 10.1038/sj.onc.1207583 · DOI
  61. Kovachev, 2017, Distinct modulatory role of RNA in the aggregation of the tumor suppressor protein p53 core domain, J. Biol. Chem., 292, 9345, 10.1074/jbc.M116.762096 · DOI
  62. Safari, 2019, Anomalous Dense Liquid Condensates Host the Nucleation of Tumor Suppressor p53 Fibrils, iScience, 12, 342, 10.1016/j.isci.2019.01.027 · DOI
  63. Suwiwat, 2004, Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer, Clin. Cancer Res., 10, 2491, 10.1158/1078-0432.CCR-03-0146 · DOI
  64. Gerotziafas, 2008, Clinical studies with anticoagulants to improve survival in cancer patients, Pathophysiol. Haemost. Thromb., 36, 204, 10.1159/000175158 · doi:10.1159/000175158
  65. Falanga, 2007, Heparin in tumor progression and metastatic dissemination, Semin. Thromb. Hemost., 33, 688, 10.1055/s-2007-991536 · doi:10.1055/s-2007-991536
  66. Alur, 2016, Anti-tumor effects of bemiparin in HepG2 and MIA PaCa-2 cells, Gene, 585, 241, 10.1016/j.gene.2016.03.044 · DOI
  67. Hsu, H.K., Hsu, K.H., Cheng, Y.M., Suen, H.Y., and Peng, S.F. (2018). Development and In Vitro Evaluation of Linear PEI-Shelled Heparin/Berberine Nanoparticles in Human Osteosarcoma U-2 OS Cells. Molecules, 23. · doi:10.3390/molecules23123121
  68. Karbownik, 2013, Hyaluronan: Towards novel anti-cancer therapeutics, Pharmacol. Rep., 65, 1056, 10.1016/S1734-1140(13)71465-8 · DOI
  69. Zhao, 2019, Bioengineered tumor microenvironments with naked mole rats high-molecular-weight hyaluronan induces apoptosis in breast cancer cells, Oncogene, 38, 4297, 10.1038/s41388-019-0719-4 · DOI
  70. Pedrote, 2018, Aggregation-primed molten globule conformers of the p53 core domain provide potential tools for studying p53C aggregation in cancer, J. Biol. Chem., 293, 11374, 10.1074/jbc.RA118.003285 · DOI
  71. Baud, 2018, Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines, Eur. J. Med. Chem., 152, 101, 10.1016/j.ejmech.2018.04.035 · DOI
  72. Rangel, 2019, p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells, J. Biol. Chem., 294, 3670, 10.1074/jbc.RA118.004671 · DOI
  73. Campos, 2018, Resveratrol prevents p53 aggregation in vitro and in breast cancer cells, Oncotarget, 9, 29112, 10.18632/oncotarget.25631 · DOI
  74. Cino, 2016, Aggregation tendencies in the p53 family are modulated by backbone hydrogen bonds, Sci. Rep., 6, 32535, 10.1038/srep32535 · DOI
  75. Chen, 2017, Polyarginine and its analogues inhibit p53 mutant aggregation and cancer cell proliferation in vitro, Biochem. Biophys. Res. Commun., 489, 130, 10.1016/j.bbrc.2017.05.111 · DOI
  76. Lima, 2020, Biophysical characterization of p53 core domain aggregates, Biochem. J., 477, 111, 10.1042/BCJ20190778 · DOI

Cited by

See all 56

Metadata

Authors
de Oliveira, G. A. P., Petronilho, E. C., Pedrote, M. M., Marques, M. A., Vieira, T. C. R. G., Cino, E. A., & Silva, J. L.
Venue
Biomolecules
Publisher
MDPI AG
Published
2020-04-04
Volume
10
Issue
4
Pages
548
ISSN
2218-273X
DOI
10.3390/biom10040548
Cited by
56
References
9
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (210008/2018)
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (465395/2014-7)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Status of p53 Oligomeric and Aggregation States in Cancer. https://app.cochat.ai/papers/10.3390/biom10040548
The paper
de Oliveira, G. A. P., Petronilho, E. C., Pedrote, M. M., Marques, M. A., Vieira, T. C. R. G., Cino, E. A., & Silva, J. L. (2020). The Status of p53 Oligomeric and Aggregation States in Cancer. Biomolecules. https://doi.org/10.3390/biom10040548

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.